12:47 PM EDT, 09/09/2024 (MT Newswires) -- T2 Biosystems ( TTOO ) shares were down nearly 6% in recent trading Monday as the company disclosed plans to build or buy its own laboratory to produce the T2Lyme diagnostic kit.

The company previously had plans to launch the product through a partnership.

T2Lyme is a direct-from-blood molecular diagnostic test for the early detection of Borrelia burgdorferi, the bacterium that causes Lyme disease in the US, according to T2 Biosystems ( TTOO ).

Price: 2.78, Change: -0.17, Percent Change: -5.76